Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (October 2026)
20 slides from Neurotech International's investor presentation, Oct 20, 2026
Slide 1: Redefining Treatment for Neurodevelopmental Disorders
Redefining Treatment for Neurodevelopmental Disorders Redefining Treatment for rsonal use only Neurodevelopmental Disorders Corporate Overview Mark Davies Executive Chairman October 2026 | ASX: NTI 0
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements This presentation includes forward looking statements. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “ma
Slide 3: The Problem We Are Trying to Solve
THE PROBLEM WE ARE TRYING TO SOLVE GLOBAL PATIENT UNIVERSE | REPORTED AUSTRALIAN DATA + MODELLED INTERNATIONAL ESTIMATES 43–46m estimated higher-support Autism Spectrum Disorder (ASD) population AUSTRALIA rsonal use only A large potential patient universe with NO approved therapy for core ASD sympto
Slide 4: The Story So Far: Derisking the Asset to Approval
THE STORY SO FAR Derisking the Asset to Approval NTI164 has progressed from discovery to an FDA IND cleared, proprietary clinical asset with positive trials across three paediatric neurological disorders. rsonal use only DISCOVERY & VALIDATION CLINICAL PROOF OF CONCEPT REGULATORY & DEVELOPMENT PHASE
Slide 5: Neurotech's pipeline of neurodevelopmental disorder programs
Neurotech’s pipeline comprises clinical programs in neurodevelopmental disorders of children where neuroinflammation is involved Neurotech’s pipeline comprises clinical programs in neurodevelopmental disorders of children where neuroinflammation is involved rsonal use only NTI164 Targets neuroinflam
Slide 6: Phase II/III ASD Clinical Trial Results
Phase II/III ASD Clinical Trial Results NTI164 delivered broad, clinically meaningful benefits in paediatric ASD Randomised, double-blind, placebo-controlled Phase II/III study | 54 completed the 8-week double-blind phase | Ages 8–17 with Level II/III ASD rsonal use only ADAPTIVE SOCIAL RESPONSE MOO
Slide 7: What is NTI164?
What is NTI164? A Proprietary Pharmaceutical Cannabinoid Derived Formulation rsonal use only ❶ Disease-modifying and potentially transformative therapy in paediatric ❼ Safe and effective in non- neurodevelopmental disorders clinical and clinical studies ❻ Notice of Allowance from USPTO ❷ Full-spectr
Slide 8: Seed to Pharmacy: End-to-End Control of NTI164
SUPPLY CHAIN Seed to Pharmacy: End-to-End Control of NTI164 One controlled chain from grow to the patient – the foundation of a reproducible full-spectrum medicine rsonal use only GROW MONITOR CONTROL EXTRACT DELIVER Consistent extract – Proprietary Know how Chemotype fidelity Traceability Patient s
Slide 9: NTI164 Peer-Reviewed Evidence Base
NTI164 Peer-Reviewed Evidence Base From bench to double-blind trial: every stage of the NTI164 programme is published in peer-reviewed journals. rsonal use only 2024 2024 2025 2026 2026 cover to add cover to add Advances in Biomolecules J Paediatr Child Health Neurotherapeutics Neurotherapeutics Com
Slide 10: Commenced dosing Phase III BEYOND HARMONY clinical trial in ASD
Commenced dosing Phase III BEYOND HARMONY clinical trial in ASD Commenced dosing Phase III BEYOND HARMONY clinical trial in ASD rsonal use only Placebo Patient Population: n = 100* Follow-Up RANDOMISATION Blinded Treatment SCREENING • ASD Level II or III Period Open-Label Extension • Total 24-week •
Slide 11: ASD Phase III roadmap and value inflection points
ASD Phase III roadmap and value inflection points ASD Phase III roadmap and value inflection points rsonal use only HREC ethics approval Clinical site initiation Patient recruitment Phase III clinical data 1Q CY26 1Q CY26 3Q CY26 2Q CY27 Phase III program supported by clinical data: • Statistically
Slide 12: Advancing our global regulatory and commercialisation strategy
Advancing our global regulatory and commercialisation strategy Advancing our global regulatory and commercialisation strategy Protecting NTI164 Advancing NTI164 rsonal use only • In July 2026 NTI announced Notices of Allowance received • In July 2026 NTI announced FDA IND cleared to proceed from USP
Slide 13: Case Study: Vertanical VER-01 (Exilby) for chronic back pain
Case Study: Vertanical VER-01 (Exilby) for chronic back pain Full spectrum extract pharmaceutical cannabinoid therapy 18 May 2026: US FDA Grants Breakthrough Therapy Designation to VER-01, an investigational cannabis-based chronic back pain treatment with Phase 3 clinical data rsonal use only Year M
Slide 14: Autism Spectrum Disorder Competitive Pipeline
Autism Spectrum Disorder Competitive Pipeline rsonal use only Preclinical / Phase 1 Phase 2 Phase 3 Approved CORE SYMPTOMS CORE SYMPTOMS RO6953958 L1-79 NTI164 Risperidone Roche, phase 1 PK study in healthy Yamo Pharmaceuticals, targets core Targets neuroinflammation and core Irritability / aggressi
Slide 15: Partnering opportunity for NTI164 is substantial
Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential Licensing Transactions Licensee Licensor Key Asset(s) Key Indicati
Slide 16: ASX-listed clinical stage peers: Phase comparables
AS AT 13 Oct 2026 ASX-listed clinical stage peers: Phase 3 comparables Neuren Pharmaceuticals Limited (ASX: NEU) Dimerix Limited (ASX: DXB) ~A$132M Trofinetide (approved, Rett syndrome) + NNZ-2591: Phase ~A$2.6B rsonal use only III in Phelan-McDermid syndrome DMX-200: Ph III in Focal Segmental Glome
Slide 17: Neurotech corporate fundamentals
AS AT 13 Oct 2026 Neurotech (ASX:NTI) Neurotech (ASX:NTI) Developing a pharmaceutical cannabinoid therapy for neurological disorders supported by rigorous clinical evidence rsonal use only Huge Market Potential Corporate Fundamentals Addressing high-growth neurological markets Market Capitalisation:
Slide 18: Neurotech Board and management
Neurotech Board and management bring extensive international experience in drug development, finance and commercialisation Neurotech Board and management bring extensive international experience in drug development, finance and commercialisation rsonal use only Mr Mark Davies Mr Andrew Chapman Mr Ma
Slide 19: Value-driving catalysts on the horizon
Value-driving catalysts on the horizon Value-driving catalysts on the horizon rsonal use only CY2026 Human Research Ethics Committee approval for ASD registration-enabling study 1Q CY2026 Initiation of first clinical site 1Q CY2026 IND submission 1H CY2026 First patient enrolled in ASD clinical tria
Slide 20: Thank You & Contact Details
Thank You Contact Details Thank You & Contact Details rsonal use only Neurotech Investor Relations: info@neurotechinternational.com www.neurotechinternational.com Neurotech International Limited (ASX: NTI) This presentation has been authorised by the Board of Neurotech International Limited This pre
Neurotech International — Investor Presentation (October 2026) on 6ix